PRGONYSEPharmaceutical PreparationsFiscal year ends December 31

PERRIGO Co plc

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$16.09−0.54 (-3.25%)

Close on Oct 19, 2026

Market cap: $2.25B
P/E (TTM): –
Dividend yield: 7.21%

PERRIGO Co plc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2015 2015-06-27	FY 2014 2014-06-28	FY 2013 2013-06-29
Revenue	4,253	4,373	4,656	4,452	4,139	4,088	3,870	4,732	4,946	4,227	3,914	0.80
Cost of Revenue	2,759	2,831	2,975	2,996	2,723	2,593	2,436	2,900	2,967	2,583	2,462	2,260
Gross Profit	1,495	1,543	1,680	1,455	1,416	1,495	1,434	1,832	1,980	1,644	1,452	1,280
Research & Development	95	112	123	123	122	122	119	219	168	188	153	115
Selling, General & Admin	962	1,015	1,164	1,097	1,018	1,024	1,015	1,032	1,060	704	620	426
Selling & Marketing	527	547	642	585	536	546	539	596	598	319	209	186
General & Administrative	436	468	522	512	482	479	477	436	461	385	411	240
Advertising Expenses	133	135	139	119	131	131	143	159	145	56	41	26
Operating Expenses	2,617	1,430	1,529	1,377	1,006	1,230	1,259	1,595	1,381	972	881	601
Operating Income	-1,122	113	152	79	410	265	175	237	598	673	571	679
Income from Equity Investments	–	-1.50	-1.90	-1.50	-1.10	–	–	–	0.30	12	-8.70	–
Other Non-Operating Income	-13	0.90	10	-53	-27	-16	69	-6.10	10	-334	-25	-0.90
Merger & Restructuring Charges	72	110	42	43	17	3.20	26	21	61	5.10	47	2.90
Asset Impairment Charges	1,363	89	90	0	173	0	14	224	48	6.80	6.00	0
Gain (Loss) on Investments	0.10	-0.20	-0.40	-0.40	-2.00	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-1.60	6.40	0	-1.40	48	-21	72	0	0	–	0	0
Pretax Income	-1,298	-81	-8.30	-139	259	–	–	291	280	260	304	608
Income Tax Expense	104	80	-3.90	-8.20	390	-38	-11	160	161	124	71	166
Income from Continuing Operations	-1,402	-161	-4.40	-131	-131	44	159	–	–	–	205	442
Income from Discontinued Operations	-23	-11	-8.30	-9.70	62	-207	-13	–	–	–	0	0
Net Income	-1,425	-172	-13	-141	-69	-163	146	131	120	136	233	442
EPS (Basic)(per share)	-10.29	-1.25	-0.09	-1.04	-0.52	-1.20	1.07	0.95	0.84	0.97	2.02	4.71
EPS (Diluted)(per share)	-10.29	-1.25	-0.09	-1.04	-0.52	-1.19	1.07	0.95	0.84	0.97	2.01	4.68
Shares Outstanding (Basic, Weighted)(shares)	139	137	135	135	134	136	136	138	142	139	115	94
Shares Outstanding (Diluted, Weighted)(shares)	139	137	135	135	134	137	137	138	143	140	116	95
Dividend per Share(per share)	1.16	1.10	1.09	1.04	0.96	0.90	0.82	0.76	0.64	0.46	0.39	0.35
EBITDA	-785	439	511	418	723	650	571	660	1,043	931	778	839
Net Interest Income	–	–	-174	-156	-125	-128	-118	-128	-168	-146	-104	-66

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 27, 2026

Profitability, TTM

Gross margin: 33.3%
Operating margin: -37.7%
Net margin: -41.9%
Return on equity, FY2025: -39.3%

Financial strength

Current ratio: 2.32
Debt to equity: 1.31
Debt to assets: 43.3%
Cash to current liabilities: 37.9%

Valuation

P/E ratio: –
Price to sales: 0.54
Price to book: 0.89
Dividend yield: 7.21%